Jordan-based MS Pharma has struck a deal with Insud Pharma subsidiary Mabxience to commercialize its bevacizumab biosimilar in the Middle East and North Africa region. The move comes after Mabxience partnered with Zentiva to commercialize bevacizumab in 21 European countries. Meanwhile, MS Pharma has also partnered with Alvion Pharma for rosuvastatin/ezetimibe in the MENA region.
Jordan-based MS Pharma has announced entering into an agreement with mAbxience S.L. to commercialize the firm’s bevacizumab biosimilar in the Middle East and North Africa region.
Without disclosing the terms of the agreement, MS Pharma said that the Alymsys (bevacizumab) biosimilar rival to Avastin, that Mabxience...